Table of Contents
Thrombosis
Volume 2012 (2012), Article ID 758385, 9 pages
http://dx.doi.org/10.1155/2012/758385
Review Article

Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?

1Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, M365 Starling Loving Hall, 410 W 10th Avenue, Columbus, OH 43210, USA
2Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, A454 Starling Loving Hall, 410 W 10th Avenue, Columbus, OH 43210, USA

Received 29 June 2012; Accepted 10 August 2012

Academic Editor: Lars Carl Borris

Copyright © 2012 Ludmila Katherine Martin and Tanios Bekaii-Saab. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Venous thromboembolism (VTE) is a frequent complication of gastrointestinal cancers that increases morbidity and may impact mortality. Low-molecular-weight heparins (LMWHs) and vitamin K antagonists (VKAs) are standard anticoagulation options for the ambulatory gastrointestinal cancer patient with VTE, but both of these agents are challenging to use for various reasons. Novel oral anticoagulants (NOAs) are new, orally available anticoagulants designed to be easier to administer with more reliable pharmacokinetics that eliminate the need for frequent monitoring of various laboratory parameters. This paper reviews the existing efficacy and safety data for the use of NOAs dabigatran etexilate, rivaroxaban, and apixaban and discusses the potential role of these agents in the management of gastrointestinal cancer-related VTE.